Markets

Valion Bio Announces Velocity Bioworks' Capabilities To Support Biotechnology Firm Mulling U.S.-Based Production For Biologics Programs

Oct 14, 2026 · 08:19 AM ET· updated 1h ago

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation,

Why It Matters

Valion Bio found a partner to help make medicines in the USA. This shows the company is moving closer to actually producing its drugs.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VBIO1.50

-0.05 (-3.23%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.